pr phqr´ sulhgdv · p 1u 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*
TRANSCRIPT
![Page 1: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/1.jpg)
![Page 2: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/2.jpg)
1
e. prof. p. dr. Romualdas
doc. dr. Audra
doc. dr. Jurgis BOJARSKAS
dr. Audrius
habil. dr. Robertas
prof. habil. dr. Vida Marija
doc. dr. Remigijus
dr. Virgilijus
doc. dr. Sabina , Lundo universitetas, Švedija
doc. dr. Aleksandras KIBARSKIS
prof. habil. dr. Limas
doc. habil. dr. Alvydas
prof. habil. dr. Vanda
prof. habil. dr. Antanas
prof. habil. dr. Alvydas
prof. habil. dr. Juozas
doc. dr. Raimondas
doc. dr. Vytautas
prof. Arvydas
prof. habil. dr. Povilas ,
prof. habil. dr. Remigijus
dr. Regina
(8*698) 4 43 13
(8*610) 0 73 05
(8*37) 33 10 09
Maketuotoja Asta
El. paštas: [email protected] internete: http://www.medicine.ltRedakcijos tel.: prenumerata (8*37) 33 09 77, (8*5) 237 52 14
reklama (8*37) 33 10 09, (8*37) 33 15 59faksas (8*37) 33 15 34
Vilniaus biuro tel. (8*5) 237 52 14
A............................................................. 2
........................................................... 4
A............................................................... 6
................... 8..................................................... 10
A....... 13
............ 15
antipsichozinis vaistas........................................................................... 17Escitalopramo (Cipralex) farmakodinaminio poveikio ypatumai ......... 21Atipiniai antipsichoziniai vaistai. Kokie jie?............................................ 24
.................................................................... 27
................................................................................... 30
I............... 32
.................................................. 34......................................... 35
prie šio ryšio sampratos ........................................................................ 37........ 39
................................................................................... 40
S............. 42
............................................................................. 44
A............................................................................ 46
Psichoterapija gerontopsichiatrijoje .......................................................... 47Psichoterapija internetu .............................................................................. 49
.......................................... 51Atviras laiškas .............................................................................................. 52
I............................................................... 53
........................ 43, 48, 51, 54
SKELBIMAI............................................................................................. 55
![Page 3: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/3.jpg)
2
-
--
--
---
-
-
--
--
-
--
---
-
-
-
-
--
-
Globalizacijos procesas ir depresija
![Page 4: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/4.jpg)
3
-
--
-
-
--
-
-
-
--
-
--
-
-
-
-
-
-
--
--
-
-
-
-
Medicinos centras „Neuromeda“ ___________________________________________________________________________
![Page 5: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/5.jpg)
4
-
-
-
-
--
--
-
-
--
-
---
-
-
Nuotr.
![Page 6: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/6.jpg)
5
-
-
-s
--
-
--
-
-
-
--
--
-
-
-
-
-
--
-
-
--
---
-
-
-
-
-
-
![Page 7: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/7.jpg)
6
-
--
-
-
-
-
--
-
--
---
---
-
-
-
-
-
-
--
-
-
-
-
-
![Page 8: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/8.jpg)
7
-
-
-
---
-
-
-
-
-
-
-
--
-
--
-
-
-
-
--
-
--
-
-
-
-
-
__________________________________________________________________________
-
![Page 9: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/9.jpg)
8
-
-
-
--
-
-
-recepto-
-
-
renijos simptomus, o hipo-
in vivo--
-
--
-
-
-
anesthetic dissociatives
Kanabinoidai
Paranoja
Nestipriai išreikštas Nestipriai išreikštas Nestipriai išreikštasNestiprus
Priešiškumas NedidelisNesunki NeNesunki Nesunki Nesunki
Ne Ne
haliucinacijos
![Page 10: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/10.jpg)
9
-
--
--
--
--
--
-
-
-
-
-
---
-
-
--
-
--
-
--
-
-
--
-
--
-
![Page 11: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/11.jpg)
10
--
-
--
-
-
--
-
--
-
-
-
-
-
---
--
-
-
-
-
-
-
--
-
---
-
-
-
-
![Page 12: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/12.jpg)
12
-
--
-
-
-
--
-
-
-
--
--
-
-
---
-
-
-
--
-
-
--
--
-
-
--
--
-
___________________________________________________________________________-
rd
![Page 13: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/13.jpg)
13
-
--
-
-
-
-kamentai,
-
-
--
-
-
tankio cholesterolio kiekis,kiekis,
---
-
-
-
rezistentiškumas insulinui,-
--
-
![Page 14: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/14.jpg)
14
-
-
, dopami-,
-
-
--
-
-
-
American Psychiatric Associa-tion, AmericanDiabetes Association, Vaistas
Klozapinas +++ + ++++ + +++
ZiprazidonasAripiprazolisAmisulpridas*
-
-
-
-
-
-
-
-
-
__________________________________________________________________________
![Page 15: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/15.jpg)
15
--
-
-
-
-
-
-
-
-
-
-
---
--
--
--
--
-
--
--
-
-
-
![Page 16: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/16.jpg)
16
-
-
-
--
--
-
-
--
--
-
--
-
--
chomotorinis slopinimas, dezorientacija, kalbos sutrikimas
-
-
--
-
-menis, paskelbtus atlikus atsitiktine atranka paremtus kontro-
__________________________________________________________________________
-
-
![Page 17: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/17.jpg)
17
-
-
-
receptorius,
-
-
-
-
-
-
-
-
-
-
--
-
-
-
---
-
-
-
![Page 18: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/18.jpg)
18
PAN
SS b
endr
o ba
lo
Aripiprazolis,
Aripiprazolis,
Placebas
*
*** *
***
**** **
** ****
-
-
--
--
-
-,-
--
-
-
-
-
-
risperidonas, haloperidolis receptorius ir
Aripiprazolis,
Aripiprazolis,
*
*
p p
***
**
![Page 19: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/19.jpg)
20
-
-
-
-
-
-
-
-
-
---
-
-,
-
---
-
-
--
--
-
-
-
--
-
--
________________________________________________________________________
-
-
![Page 20: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/20.jpg)
21
---
sijos,
--
-
-
-
-
-
-
-
--
-
-
-
receptoriai
Cipralex
![Page 21: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/21.jpg)
22
--
--
--
-
-
-
-
-
-
-
receptorius,
-
-
-
-
--
-
-
-
--
--
-
-
________________________________________________________________________-
-
-
-
![Page 22: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/22.jpg)
23
![Page 23: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/23.jpg)
24
---
--
-
--
---
-
-
-
-
histamino recep-
-
-
-
APV-
-
-
--
--
-
-receptorius blokuojantis
-
-
-
-
![Page 24: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/24.jpg)
26
-
-
-
-
--
--
-
-
-
---
-
--
-
-
-
-
-
-
-
-
--
___________________________________________________________________________
-
![Page 25: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/25.jpg)
27
siste-neuro-
-
-
-
-
--
-
-
--
-
-
recepto-
-
-
-
---
-
-
---
--
-
LISURIDAS
---
![Page 26: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/26.jpg)
28
-
-
-
-
-
-
-
-
-
--
--
-
-
-
-
-
-
-
-
-
___________________________________________________________________________-
-
![Page 27: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/27.jpg)
30
-
--
-
-
-
-
-
-
-
-
-
-
-
--
-
-
---
-
-
-
-
![Page 28: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/28.jpg)
31
--
monotera-
--
--
-
-
-
-
-
-
__________________________________________________________________________
-
-
-
-
Politerapija
-terapija
-
![Page 29: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/29.jpg)
32
-
--
ir-
-
-
-
-
--
ir--
-
-
-
-
-
-
--
--
-
-
--
![Page 30: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/30.jpg)
33
--
-
-
--
-
-
---
-
Levodopos preparatai-
-
-
Dopamino agonistai -
-
-
-
Pramipeksolis-
-
-
-
Benzodiazepinai
Vaistai nuo epilepsijos.-
Amantadinas, -
-
-
-
--
-
--
-
--
-
-
________________________________________________________________________
-
![Page 31: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/31.jpg)
34
-
--
--
-
-
-
-
--
--
-
-
-
-
-
-
tokiems pacientams atipiniaiAPV rekomenduojami kaip pirmos ei-
-
--
-
-
---
--
-
___________________________________________________________________________-
-
![Page 32: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/32.jpg)
35
--
-
-
--
-
-
-
---
-
-
-
-
-
-
-
-
-
-
Miego higiena.
--
--
![Page 33: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/33.jpg)
36
-
--
Miego ribojimo terapija. -
---
-
-
---
--
--
-
-
--
-
SOMNOLS
-
-
--
-
-
-
-
-
--
riant hip-
___________________________________________________________________________
![Page 34: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/34.jpg)
37
-
--
-
---
-
-
--
-
-
---
-
--
-
-
--
--
-
--
--
-
prie šio ryšio sampratos
![Page 35: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/35.jpg)
38
-
--
-
-
-
--
-
-
-
-
--
-
-
-
-
-
-
-
-
--
-
-
__________________________________________________________________________-
-
-
-
![Page 36: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/36.jpg)
39
-
--
-
--
--
-
--
-
-
-tine
-
-
-
--
-
--
-
-
-
-
-
_____________________________________________________________________________
antidepresantas
![Page 37: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/37.jpg)
40
--
--
-
-
-
-
-
-
-
priešiškumas
sutrikimai
-
-tina prisiminti, kad -
-
-
-
![Page 38: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/38.jpg)
41
-
.
-
-
-
--
--
-
-
-
-
-
-
-
-
__________________________________________________________________________
-
-
-
Pav.
***
*** ***
***
***
*** *****
***
****
***
![Page 39: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/39.jpg)
42
---
--
-
-
--
--
sindromo su retencijos
-
--
-
-
-
- -
![Page 40: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/40.jpg)
43
--
-
-
-
-
---
-
-
-
-
-
-
--
-
-
-
-
-
-
-
-
![Page 41: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/41.jpg)
44
--
--
-
Neretai katatonija atsiranda kaip pereinamasis etapas
-
--
-
-
-
--
-
-
-
-
--
-
-
-
-
--
![Page 42: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/42.jpg)
45
-
--
-
-
--
--
-Psichiat-
-
-
Gydymas
---
-
-
-
--
-
-
-
-
-
-
--
______________________________________________________________________-
m
![Page 43: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/43.jpg)
46
-
-
-
-
-
-
-
-
-
-
-
-
__________________________________________________________________________
-
-
-
![Page 44: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/44.jpg)
47
-sionalo prieinamumu,
paties paciento pasirinkimu,
-
-
-
-
-
-
-
-
-
-
-
-
-
--
-
![Page 45: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/45.jpg)
48
nas sunkumas, su kuriuo susiduria specialistai dirbdami šioje
-
-
-
--
-
-
-
-
-
-
-
-
-moksta iš šios terapijos metu naudojamo psichoedukacinio
-
-
-
-
__________________________________________________________________________
-
-
,
-
![Page 46: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/46.jpg)
49
--
-
-
---
-
---
--
-
-
mis
--
--
---
-
-
-
-
-
--
-
-
-
![Page 47: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/47.jpg)
50
-
--
-
-
-
-
-
-
-
-
--
---
--
-
pri-
---
---
-
-
-
--
-
-
-
-
-
-
__________________________________________________________________________
-
![Page 48: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/48.jpg)
51
-
--
---
-
ir
-
--
-
-
-
-
-
-
-
-
-
--
--
-
-
--
-
-
-
-
![Page 49: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/49.jpg)
52
--
-
-
--
-
-
-
-
-
-
-
--
-
-
--
-
-
![Page 50: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/50.jpg)
53
-
--
--
-
-a – -
-
-
-t
-
-
-
-
-
-
-
-
--
---
--
-
-
![Page 51: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/51.jpg)
54
, tam tikros kompli-
-
-
-
-
--
-
-
-
-
--
-
-
-
-
-
--
-
-
-
-
--
--
![Page 52: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/52.jpg)
55
Gerb. daktare,
-
-
-
-
-
-
pm, t, t
![Page 53: PR PHQR´ SULHGDV · P 1U 1(59 ,5 36,&+,.26 /,*261 æ851$/2 Å*](https://reader036.vdocuments.site/reader036/viewer/2022080718/5f78d07f10a4a640d51eaa9a/html5/thumbnails/53.jpg)
56